What is an pleasing α/β appeal for manager and collar cancer and for brain stem (or spinal cord).?
what is an acceptable α/β value for head and collar cancer and for brain stem (or spinal cord)?Thanks!
Answers: In a report published by the International Journal of Radiation Oncology Biology Physics Volume 56, Issue 2, 1 June 2003, Pages 573-585, describing the dosimetric analyses of a Phase I/II protocol, designed to examine the capabilities of an institutionally developed intensity-modulated radiotherapy (IMRT) system with respect to dose escalation. The protocol employed stringent dosimetric guidelines in the treatment of locally advanced head-and-neck squamous cell carcinomas (HNSCC) near radiotherapy alone using IMRT and the simultaneous integrated boost (SIB) technique. The published results were - Mean doses to 98% of GTV were 68.4 Gy, 70.5 Gy, and 70.8 Gy, and average GTV dose homogeneity was 6.7%, 7.6%, and 8.8% for the three cohorts. The average doses to the parotid gland proximal to and distant from GTV be 41.3 Gy and 25.7 Gy, respectively. Dose distributions measured in phantom showed good agreement with calculation. The conclusion was - Treatment of locally advanced HNSCC using SIB-IMRT as described is feasible. Treatment planning and delivery are safer and more streamlined than with conventional three-dimensional processes. Predicted dose distributions can be accurately delivered with excellent conformality using dynamic MLC. At most minuscule one of the parotid glands can be adequately spared. Patient follow-up continues and will allow eventual quantitative correlation of delivered dose distributions with clinical outcomes.
Hope this help
matador 89
Where can you buy spinal or backbone support items?
Spinal block whats the pros and cons of it?
SPINAL fusion?
One of the bones within my spinal cord species of hurts or ache when i bend fund or press on it.?
Nape piercings = possibility of Spinal infection?
Answers: In a report published by the International Journal of Radiation Oncology Biology Physics Volume 56, Issue 2, 1 June 2003, Pages 573-585, describing the dosimetric analyses of a Phase I/II protocol, designed to examine the capabilities of an institutionally developed intensity-modulated radiotherapy (IMRT) system with respect to dose escalation. The protocol employed stringent dosimetric guidelines in the treatment of locally advanced head-and-neck squamous cell carcinomas (HNSCC) near radiotherapy alone using IMRT and the simultaneous integrated boost (SIB) technique. The published results were - Mean doses to 98% of GTV were 68.4 Gy, 70.5 Gy, and 70.8 Gy, and average GTV dose homogeneity was 6.7%, 7.6%, and 8.8% for the three cohorts. The average doses to the parotid gland proximal to and distant from GTV be 41.3 Gy and 25.7 Gy, respectively. Dose distributions measured in phantom showed good agreement with calculation. The conclusion was - Treatment of locally advanced HNSCC using SIB-IMRT as described is feasible. Treatment planning and delivery are safer and more streamlined than with conventional three-dimensional processes. Predicted dose distributions can be accurately delivered with excellent conformality using dynamic MLC. At most minuscule one of the parotid glands can be adequately spared. Patient follow-up continues and will allow eventual quantitative correlation of delivered dose distributions with clinical outcomes.
Hope this help
matador 89
The information post by website user , Helpde.com not guarantee correctness.